Which electrolyte abnormality is commonly associated with ACEIs?

ACE inhibitors (ACEIs) are commonly associated with hyperkalemia, which is an elevated level of potassium in the blood. This occurs because ACEIs inhibit the renin-angiotensin-aldosterone system (RAAS), leading to decreased aldosterone production. Aldosterone typically promotes the excretion of potassium in the kidneys. When this hormone's levels decrease due to the action of the ACEI, potassium is retained, which can result in hyperkalemia.

In the context of heart and kidney function, it is crucial to monitor potassium levels in patients who are prescribed ACE inhibitors, particularly those with underlying renal issues or other risk factors for hyperkalemia. Recognizing this side effect is important in clinical practice for the safe management of patients receiving ACEI therapy. Consequently, hyperkalemia is the most commonly encountered electrolyte abnormality in this scenario, making it the correct answer.